Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MTL Cannabis Corp C.MTLC

Alternate Symbol(s):  MTLNF

MTL Cannabis Corp. is focused on crafting cannabis products, including lines of dried flower, pre-rolls and hash marketed. The Company, through its subsidiaries, is engaged in the cultivation and production of cannabis products for recreational and medical purposes in Canada. It also operates clinics that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from medical conditions. Its wholly owned subsidiaries include Montreal Medical Cannabis Inc. (Montreal Cannabis), Abba Medix Corp. (Abba), Canada House Clinics Inc. (CHC), and IsoCanMed Inc. (ICM). Montreal Medical is a licensed producer operating from a 57,000 sq ft licensed indoor growing facility in Pointe Claire, Quebec. Abba is a licensed producer in Pickering, Ontario that operates a medical cannabis marketplace. CHC is operating clinics across Canada. ICM is a licensed producer in Louiseville, Quebec growing indoor cannabis in its 64,000 sq. ft. production facility.


CSE:MTLC - Post by User

Comment by Tomcaton Sep 30, 2021 5:16pm
258 Views
Post# 33947620

RE:We are all done for.

RE:We are all done for.YOu have to add three zeros to the numbers you posted. Everything is usually listed in thousanands.

  • Cash position was $741,000 as at July 31, 2021 compared to $1,835,000 as at April 30, 2021.
     
  • Revenue was $4,024,000, an increase of $1,497,000 or 59%, compared to $2,527,000 during the same period in the prior year.
     
  • Loss and Comprehensive Loss for the three months was $2,575,000, an increase of $1,943.000 or 307% compared to a loss of $632,000 during the same period in 2020. Loss and Comprehensive Loss for the three months ending July 31, 2021 included a one-time inventory impairment of $1,004,000 and there was an unrealized gain on changes in fair value of biological assets of $712,000 in the same period of the prior year.
     
  • Cash flow used in operating activities was $347,000, an increase of $69,000 or 25%, compared to $278,000 during the same period in 2020.
     
  • Cash flow used in investing activities was $576,000 during the three months ending July 31, 2021$131,000 of net cash was provided by the investing activities during the same period in the prior year.
     
  • Net cash used in financing activities was $171,000 compared to $268,000 during the same period in 2020.
     
  • Shareholder's equity was a surplus of $4,484,000 compared to $6,873,000 as of April 30, 2021.

<< Previous
Bullboard Posts
Next >>